Pelthos Therapeutics Inc. PTHS
22.19
(0.21)
(0.94%)
as of 25 Sep
- Market cap
- $85.8M
- P/E
- 0.0×
Follow PTHS
Insider Buys
alert about insiders buying in the last 12 month
| Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — | 0.00 |
P/S ratio |
— | — | — | — | 0.00 |
P/FCF ratio |
— | — | — | — | 0.00 |
P/Operating CF |
— | — | — | — | (9.32) |
P/B ratio |
— | — | — | — | 1.50 |
Price to Tangible BV |
— | — | — | — | 0.00 |
EV/Sales |
— | — | — | — | 0.00 |
EV/EBITDA |
— | — | — | — | 0.00 |
EV/Operating CF |
— | — | — | — | (3.28) |
EV/FCF |
— | — | — | — | (3.28) |
Quick Ratio |
0.00 | 0.01 | 0.01 | 0.13 | 1.03 |
Current Ratio |
0.00 | 0.01 | 0.01 | 0.34 | 2.05 |
Net Debt/EBITDA |
0.00 | (0.22) | (0.13) | (0.24) | (0.45) |
Debt/Assets |
0.00% | 980.76% | 987.97% | 159.68% | 24.11% |
Debt/Equity |
0.00 | (0.15) | (0.15) | (0.81) | 0.81 |
Asset Turnover |
— | 0.00 | 0.00 | 0.00 | 0.25 |
Operating CF/Net income |
2.68 | 0.64 | 0.13 | 0.73 | 0.52 |
Capex/Depreciation |
— | 0.00 | 0.00 | 0.00 | (0.04) |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| 0.00% | 66.57% | 145.42% | 173.72% | (239.55%) | |
| 0.00% | (8,924.14%) | (9,743.63%) | (1,085.71%) | (65.75%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | (38.76%) |
Return on Tangible Assets |
23.07% | 66.33% | 114.53% | 293.11% | (117.07%) |
Average Days of Receivables |
— | — | — | — | 192.51 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 7.31% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 252.77% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.49 |
Share Based Compensation of Revenue |
— | 0.00% | 0.00% | 0.00% | 32.52% |
Graham Net Nets |
— | — | — | — | (0.65) |
Graham Number |
— | — | — | — | 0.00 |
Earnings Yield |
— | — | — | — | (74.55%) |
Free Cash Flow Yield |
— | — | — | — | (38.75%) |
Revenue per Share |
— | 0.00 | 0.00 | 0.00 | 8.93 |
Operating CF per Share |
0.00 | (36.03) | (7.68) | (10.39) | (12.01) |
Capex per Share |
— | 0.00 | 0.00 | 0.00 | (0.05) |
Free Cash Flow per Share |
0.00 | (36.03) | (7.68) | (10.39) | (12.07) |
Cash per Share |
— | 1.27 | 0.75 | 0.92 | 9.58 |
Shareholders Equity per Share |
0.00 | (85.21) | (50.47) | (4.87) | 20.68 |
Interest Debt per Share |
— | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.00 | (85.21) | (50.47) | (4.87) | 20.68 |
Free Cash Flow |
(1.59) | (1.57) | (0.98) | (5.79) | (22.69) |
Working Capital |
(2.58) | (3.71) | (6.44) | (2.71) | 27.42 |
Capital Expenditures |
— | — | — | — | (0.10) |
Net Current Asset Value |
(3.68) | (3.71) | (6.44) | (2.71) | (38.11) |
EV/EBIT |
— | — | — | — | 0.00 |
Capex to Sales |
— | — | — | — | 0.01 |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | (257.93%) |
Price to Operating Income |
— | — | — | — | 0.00 |
| Other line items | |||||
Depreciation/Fixed assets |
— | 0.00 | 0.00 | 0.00 | 0.27 |
Cash ROIC |
43.28% | 50.37% | 18.18% | 38,613.33% | (36.42%) |
Accounts Receivable Turnover |
— | — | — | — | 0.00 |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.00 | 1.63 |
Inventory Turnover |
— | — | — | — | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 273.29 |
Days of Inventory on Hand |
— | — | — | — | 2,157.60 |
Average Payables |
— | 2.79 | 3.81 | 3.26 | 2.44 |
Average Assets |
— | 0.03 | 0.08 | 0.73 | 65.88 |
Average Common Equity |
— | (3.69) | (5.08) | (4.58) | 18.08 |
Columns are period end dates